Federally-funded research has played a role in every major advance in cancer prevention, detection and treatment. But we need more!
By increasing funding for breast cancer programs at the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH) and Department of Defense (DOD), we can end breast cancer once and for all.
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which is a partnership between the CDC and state departments of health, provides potentially lifesaving breast cancer screening and diagnostic services to low-income, uninsured and underinsured women who do not qualify for Medicaid. NBCCEDP also provides public education, outreach, patient navigation, care coordination and quality assistance to increase screening rates and reach underserved populations.
Since 1991, NBCCEDP has provided more than 13.2 million breast and cervical cancer screening exams to more than 5.5 million women, detecting nearly 89,000 breast cancers and 4,600 cervical cancers. However, at current funding levels, NBCCEDP serves less than 10 percent of the estimated number of eligible women. Without access to early detection programs, many uninsured and underinsured women are forced to delay or forgo screenings, which can lead to later-stage breast cancer diagnoses.
This is why we are calling on Members of Congress to preserve women’s access to breast cancer screening and diagnostic services by funding the National Breast and Cervical Cancer Early Detection Program at $275 million in the FY21 budgets.
The 3.8 million breast cancer survivors in the U.S. are testaments to the progress achieved through research, but more still needs to be done for the 42,000 women and men expected to die from the disease this year. Biomedical research not only defends Americans against cancer and other diseases, but also serves as one of our nation’s primary paths to innovation, global competitiveness and economic growth.
We urge Congress to make biomedical research an unwavering national priority by funding the National Institutes of Health at $44.7 billion in the FY21 budget.
The Department of Defense (DOD)Breast Cancer Research Program (BCRP) has touched every significant breast cancer advance in recent history. BCRP challenges scientists to pursue high-risk, high-reward research, explore new paradigms that could lead to critical discoveries and make an unprecedented impact on breast cancer. Since 1992, the federal government has invested more than $3.6 billion in the CDMRP on breast cancer, in support of over 6,800 grants, and resulting in over 1,100 patents. We must continue to foster this success.
Our last funding request to Congress is to make the innovative breast cancer research conducted at the Department of Defense a priority by funding the Breast Cancer Research Program at $160 million in the FY21 budget.
Please ask your lawmakers to increase funding for these life-saving programs!